- Home
- MRM vs CNSP Comparison
MRM vs CNSP Comparison
Compare MRM & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- CNSP
- Stock Information
- Founded
- MRM 2000
- CNSP 2017
- Country
- MRM Japan
- CNSP United States
- Employees
- MRM 1101
- CNSP N/A
- Industry
- MRM Other Consumer Services
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- CNSP Health Care
- Exchange
- MRM Nasdaq
- CNSP Nasdaq
- Market Cap
- MRM 5.9M
- CNSP 5.6M
- IPO Year
- MRM 2020
- CNSP 2019
- Fundamental
- Price
- MRM $0.73
- CNSP $1.01
- Analyst Decision
- MRM
- CNSP Hold
- Analyst Count
- MRM 0
- CNSP 1
- Target Price
- MRM N/A
- CNSP N/A
- AVG Volume (30 Days)
- MRM 4.0M
- CNSP 239.3K
- Earning Date
- MRM 01-01-0001
- CNSP 05-14-2025
- Dividend Yield
- MRM N/A
- CNSP N/A
- EPS Growth
- MRM N/A
- CNSP N/A
- EPS
- MRM N/A
- CNSP N/A
- Revenue
- MRM $44,462,062.00
- CNSP N/A
- Revenue This Year
- MRM N/A
- CNSP N/A
- Revenue Next Year
- MRM N/A
- CNSP N/A
- P/E Ratio
- MRM N/A
- CNSP N/A
- Revenue Growth
- MRM 2.80
- CNSP N/A
- 52 Week Low
- MRM $0.34
- CNSP $0.77
- 52 Week High
- MRM $8.39
- CNSP $800.00
- Technical
- Relative Strength Index (RSI)
- MRM 52.73
- CNSP 36.68
- Support Level
- MRM $0.60
- CNSP $0.83
- Resistance Level
- MRM $0.90
- CNSP $1.37
- Average True Range (ATR)
- MRM 0.23
- CNSP 0.14
- MACD
- MRM 0.01
- CNSP 0.07
- Stochastic Oscillator
- MRM 44.69
- CNSP 44.82
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.